Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization

Benjamin R. Kipp, Robert Jeffrey Karnes, Shannon M. Brankley, Aaron R. Harwood, V. Shane Pankratz, Thomas J. Sebo, Michael M. Blute, Michael M. Lieber, Horst Zincke, Kevin C. Halling

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Purpose: We evaluated fluorescence in situ hybridization (FISH) for assessing the response to therapy in patients with superficial bladder cancer receiving bacillus Calmette-Guerin or other intravesical therapies. Materials and Methods: A total of 37 patients receiving intravesical therapy for superficial bladder cancer were enrolled in this study. Urine specimens were collected for FISH analysis just prior to the first intravesical therapy in 31 cases and just prior to or within 2 months following the last intravesical therapy in 37. FISH was done using the UroVysion probe set (Abbott Laboratories, Abbott Park, Illinois) with results considered positive if 5 or more cells demonstrated polysomy. Biopsy, cystoscopy and/or cytology results were then compared to FISH results to evaluate the usefulness of the test for monitoring intravesical therapy. Results: Of the patients 25 had a negative and 12 had a positive post-therapy FISH result. All 12 patients with a positive post-therapy FISH result had tumor recurrence, while tumor recurrence was observed in 13 of the 25 with a negative post-therapy FISH result (HR 4.6, 95% CI 1.9 to 11.1, p <0.001). Of the patients with tumor recurrence 7 of 12 with a positive post-therapy FISH result had muscle invasive tumor and 2 of 25 with a negative post-therapy FISH result had muscle invasive tumor (HR 9.4, 95% CI 1.9 to 45.3, p = 0.001). Conclusions: FISH appears to be useful for monitoring patients with superficial bladder cancer for the response to intravesical therapy. Patients with a positive FISH result at the end of treatment are at high risk for progression to muscle invasive bladder cancer.

Original languageEnglish (US)
Pages (from-to)401-404
Number of pages4
JournalJournal of Urology
Volume173
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Therapeutics
Neoplasms
Recurrence
Muscles
Cystoscopy
Physiologic Monitoring
Mycobacterium bovis
Cell Biology
Urine
Biopsy

Keywords

  • Bladder
  • Bladder neoplasms
  • Fluorescence
  • In situ hybridization
  • Mycobacterium bovis
  • Outcome and process assessment

ASJC Scopus subject areas

  • Urology

Cite this

Kipp, B. R., Karnes, R. J., Brankley, S. M., Harwood, A. R., Pankratz, V. S., Sebo, T. J., ... Halling, K. C. (2005). Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. Journal of Urology, 173(2), 401-404. https://doi.org/10.1097/01.ju.0000149825.83180.a4

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. / Kipp, Benjamin R.; Karnes, Robert Jeffrey; Brankley, Shannon M.; Harwood, Aaron R.; Pankratz, V. Shane; Sebo, Thomas J.; Blute, Michael M.; Lieber, Michael M.; Zincke, Horst; Halling, Kevin C.

In: Journal of Urology, Vol. 173, No. 2, 02.2005, p. 401-404.

Research output: Contribution to journalArticle

Kipp, BR, Karnes, RJ, Brankley, SM, Harwood, AR, Pankratz, VS, Sebo, TJ, Blute, MM, Lieber, MM, Zincke, H & Halling, KC 2005, 'Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization', Journal of Urology, vol. 173, no. 2, pp. 401-404. https://doi.org/10.1097/01.ju.0000149825.83180.a4
Kipp, Benjamin R. ; Karnes, Robert Jeffrey ; Brankley, Shannon M. ; Harwood, Aaron R. ; Pankratz, V. Shane ; Sebo, Thomas J. ; Blute, Michael M. ; Lieber, Michael M. ; Zincke, Horst ; Halling, Kevin C. / Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. In: Journal of Urology. 2005 ; Vol. 173, No. 2. pp. 401-404.
@article{22cd757dc3904d92a3dea8ee2277ef85,
title = "Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization",
abstract = "Purpose: We evaluated fluorescence in situ hybridization (FISH) for assessing the response to therapy in patients with superficial bladder cancer receiving bacillus Calmette-Guerin or other intravesical therapies. Materials and Methods: A total of 37 patients receiving intravesical therapy for superficial bladder cancer were enrolled in this study. Urine specimens were collected for FISH analysis just prior to the first intravesical therapy in 31 cases and just prior to or within 2 months following the last intravesical therapy in 37. FISH was done using the UroVysion probe set (Abbott Laboratories, Abbott Park, Illinois) with results considered positive if 5 or more cells demonstrated polysomy. Biopsy, cystoscopy and/or cytology results were then compared to FISH results to evaluate the usefulness of the test for monitoring intravesical therapy. Results: Of the patients 25 had a negative and 12 had a positive post-therapy FISH result. All 12 patients with a positive post-therapy FISH result had tumor recurrence, while tumor recurrence was observed in 13 of the 25 with a negative post-therapy FISH result (HR 4.6, 95{\%} CI 1.9 to 11.1, p <0.001). Of the patients with tumor recurrence 7 of 12 with a positive post-therapy FISH result had muscle invasive tumor and 2 of 25 with a negative post-therapy FISH result had muscle invasive tumor (HR 9.4, 95{\%} CI 1.9 to 45.3, p = 0.001). Conclusions: FISH appears to be useful for monitoring patients with superficial bladder cancer for the response to intravesical therapy. Patients with a positive FISH result at the end of treatment are at high risk for progression to muscle invasive bladder cancer.",
keywords = "Bladder, Bladder neoplasms, Fluorescence, In situ hybridization, Mycobacterium bovis, Outcome and process assessment",
author = "Kipp, {Benjamin R.} and Karnes, {Robert Jeffrey} and Brankley, {Shannon M.} and Harwood, {Aaron R.} and Pankratz, {V. Shane} and Sebo, {Thomas J.} and Blute, {Michael M.} and Lieber, {Michael M.} and Horst Zincke and Halling, {Kevin C.}",
year = "2005",
month = "2",
doi = "10.1097/01.ju.0000149825.83180.a4",
language = "English (US)",
volume = "173",
pages = "401--404",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization

AU - Kipp, Benjamin R.

AU - Karnes, Robert Jeffrey

AU - Brankley, Shannon M.

AU - Harwood, Aaron R.

AU - Pankratz, V. Shane

AU - Sebo, Thomas J.

AU - Blute, Michael M.

AU - Lieber, Michael M.

AU - Zincke, Horst

AU - Halling, Kevin C.

PY - 2005/2

Y1 - 2005/2

N2 - Purpose: We evaluated fluorescence in situ hybridization (FISH) for assessing the response to therapy in patients with superficial bladder cancer receiving bacillus Calmette-Guerin or other intravesical therapies. Materials and Methods: A total of 37 patients receiving intravesical therapy for superficial bladder cancer were enrolled in this study. Urine specimens were collected for FISH analysis just prior to the first intravesical therapy in 31 cases and just prior to or within 2 months following the last intravesical therapy in 37. FISH was done using the UroVysion probe set (Abbott Laboratories, Abbott Park, Illinois) with results considered positive if 5 or more cells demonstrated polysomy. Biopsy, cystoscopy and/or cytology results were then compared to FISH results to evaluate the usefulness of the test for monitoring intravesical therapy. Results: Of the patients 25 had a negative and 12 had a positive post-therapy FISH result. All 12 patients with a positive post-therapy FISH result had tumor recurrence, while tumor recurrence was observed in 13 of the 25 with a negative post-therapy FISH result (HR 4.6, 95% CI 1.9 to 11.1, p <0.001). Of the patients with tumor recurrence 7 of 12 with a positive post-therapy FISH result had muscle invasive tumor and 2 of 25 with a negative post-therapy FISH result had muscle invasive tumor (HR 9.4, 95% CI 1.9 to 45.3, p = 0.001). Conclusions: FISH appears to be useful for monitoring patients with superficial bladder cancer for the response to intravesical therapy. Patients with a positive FISH result at the end of treatment are at high risk for progression to muscle invasive bladder cancer.

AB - Purpose: We evaluated fluorescence in situ hybridization (FISH) for assessing the response to therapy in patients with superficial bladder cancer receiving bacillus Calmette-Guerin or other intravesical therapies. Materials and Methods: A total of 37 patients receiving intravesical therapy for superficial bladder cancer were enrolled in this study. Urine specimens were collected for FISH analysis just prior to the first intravesical therapy in 31 cases and just prior to or within 2 months following the last intravesical therapy in 37. FISH was done using the UroVysion probe set (Abbott Laboratories, Abbott Park, Illinois) with results considered positive if 5 or more cells demonstrated polysomy. Biopsy, cystoscopy and/or cytology results were then compared to FISH results to evaluate the usefulness of the test for monitoring intravesical therapy. Results: Of the patients 25 had a negative and 12 had a positive post-therapy FISH result. All 12 patients with a positive post-therapy FISH result had tumor recurrence, while tumor recurrence was observed in 13 of the 25 with a negative post-therapy FISH result (HR 4.6, 95% CI 1.9 to 11.1, p <0.001). Of the patients with tumor recurrence 7 of 12 with a positive post-therapy FISH result had muscle invasive tumor and 2 of 25 with a negative post-therapy FISH result had muscle invasive tumor (HR 9.4, 95% CI 1.9 to 45.3, p = 0.001). Conclusions: FISH appears to be useful for monitoring patients with superficial bladder cancer for the response to intravesical therapy. Patients with a positive FISH result at the end of treatment are at high risk for progression to muscle invasive bladder cancer.

KW - Bladder

KW - Bladder neoplasms

KW - Fluorescence

KW - In situ hybridization

KW - Mycobacterium bovis

KW - Outcome and process assessment

UR - http://www.scopus.com/inward/record.url?scp=19944433978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433978&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000149825.83180.a4

DO - 10.1097/01.ju.0000149825.83180.a4

M3 - Article

C2 - 15643180

AN - SCOPUS:19944433978

VL - 173

SP - 401

EP - 404

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -